Table 1

Attrition table of study patient population in phase I

Patient size by BM method	Breast cancer		NSCLC		Prostate cancer
Patient size by BM method	N	%	N	%	N	%
Eligible cohort at feasibility stage	6142	100	5202	100	5382	100
Patient cohort identified with BM in the medical records	573	9.3	899	17.3	1017	18.9
Patients identified by NLP of reports *	527	92.0	829	92.2	963	94.7
Patients identified as receiving BTA treatment *	309	53.9	118	13.1	129	12.7
Patients identified as patient having SCC *	19	3.3	41	4.6	42	4.1
Patients identified in coded EMR field *	49	8.6	<75	–	55	5.4
Final cohort of patients with BM after further clinical review	559	9.0	894	17.0	1013	18.8

*Number of patients identified as BM by each method of the overall eligible cohort and confirmed after review by two clinical physicians (patient can be identified in multiple methods).
BM, bone metastasis; BTA, bone-targeting agents; EMR, electronic medical record; NLP, natural language processing; NSCLC, non-small cell lung cancer; SCC, spinal cord compression.